One of the most-searched Ebola questions in 2026 is whether a vaccine or specific treatment exists for the Bundibugyo strain at the centre of the DRC outbreak. The short answer is no: as of May 2026 there is no licensed vaccine and no licensed specific antiviral or monoclonal antibody therapy for Bundibugyo virus disease. The longer answer — what is licensed for Zaire ebolavirus, what is in the Bundibugyo R&D Blueprint pipeline, and what supportive care actually does — is more useful than the headline.
Licensed Ebola countermeasures (Zaire ebolavirus only)
- Ervebo (rVSV-ZEBOV) — Merck recombinant vesicular stomatitis virus vaccine licensed in 2019 for Zaire ebolavirus. Highly effective in ring-vaccination trials during the 2018–20 DRC Kivu outbreak. Not licensed for Bundibugyo.
- Inmazeb (REGN-EB3, atoltivimab/maftivimab/odesivimab) — Regeneron three-monoclonal-antibody cocktail licensed by the FDA in 2020 for Zaire ebolavirus. Not licensed for Bundibugyo.
- Ebanga (ansuvimab-zykl, mAb114) — Ridgeback single-monoclonal-antibody therapy licensed by the FDA in 2020 for Zaire ebolavirus. Not licensed for Bundibugyo.
The Ervebo + Inmazeb + Ebanga toolkit transformed the management of Zaire ebolavirus disease over the 2018–2024 period. None of the three has demonstrated clinical efficacy against Bundibugyo virus in published trials, although cross-neutralisation has been studied at the laboratory level. Off-label use against the 2026 Bundibugyo outbreak is a decision being weighed by WHO and the DRC Ministry of Public Health on a case-by-case compassionate-use basis, but is not the operational mainline of the response.
The WHO R&D Blueprint Bundibugyo pipeline (announced 22 May 2026)
At the WHO Director-General's media briefing on outbreaks of Ebola and hantavirus on 22 May 2026, the WHO Research & Development Blueprint technical advisory group on therapeutics announced two formal Bundibugyo priorities:
- Two monoclonal antibody candidates prioritised for clinical trial. The specific candidate identities are being held inside the WHO R&D Blueprint working group until the trial protocols are filed. The published pre-clinical Bundibugyo mAb literature converges on a small number of high-avidity broadly neutralising scaffolds that have shown cross-protection in primate Bundibugyo challenge studies.
- Obeldesivir (a remdesivir-class oral nucleoside-analog antiviral) under evaluation in a clinical trial as post-exposure prophylaxis (PEP) for high-risk contacts of confirmed Bundibugyo cases — household members, healthcare workers, and other identifiable close contacts. The PEP framing is the right early-trial design because the contact rings provide a defined population for a randomised study, and preventing onward transmission inside the rings would compound across the outbreak.
WHO Director-General Tedros noted that any vaccine roll-out for Bundibugyo would take at least six to nine months — meaning the 2026 response will be carried on the supportive-care backbone with the mAb and obeldesivir trials as bridging interventions if they can be activated quickly enough.
Supportive care: what actually saves lives
In the absence of a licensed specific therapy for Bundibugyo, structured supportive care is the single highest-yield intervention. The WHO Ebola treatment centre standard of care includes:
- Aggressive intravenous fluid resuscitation to manage GI fluid loss
- Electrolyte correction (sodium, potassium, calcium) — Ebola disease produces large electrolyte derangements
- Oxygen support and management of respiratory complications
- Antimalarials and broad-spectrum antibiotics where co-infection is suspected (malaria and bacterial co-infection are common in the DRC clinical setting)
- Antipyretics and pain management
- Nutrition support — including oral rehydration solution and nasogastric feeding where indicated
The published Ebola disease literature consistently shows that patients reaching an Ebola treatment centre during the prodromal or early GI phase, and receiving structured supportive care, have meaningfully better outcomes than those who present late or never reach a treatment centre. The case-fatality rate gap between Ebola treatment centre cases and community-managed cases can be 30 percentage points or more depending on outbreak setting.
What the next 90 days of the pipeline need to show
Three operational milestones will define the Bundibugyo R&D pipeline through August 2026:
- Whether the mAb candidate trial protocols and the obeldesivir PEP trial protocol can be filed, IRB-reviewed at participating sites in DRC and Uganda, and operationally activated inside the 6-to-8-week window during which case incidence is most likely to remain at trial-feasible levels.
- Whether enough confirmed cases or high-risk contacts can be enrolled in that window to power either trial to a defensible primary endpoint. Enrollment feasibility is historically the binding constraint on outbreak-response trial science.
- Whether the field-level operational tempo of contact tracing inside Goma, Butembo and the Ituri health zones can support the close protocol monitoring that an outbreak-response trial requires.